By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



30 Worcester Road

Toronto  Ontario  M9W 5X2  Canada
Phone: 416-798-3001 Fax: 416-798-3007



Company News
IntelliPharmaCeutics Announces 2014 Year End Results With A 48% Reduction In Operating Loss 2/23/2015 7:55:51 AM
IntelliPharmaCeutics Reports The Signing Of An Exclusive Licensing And Manufacturing Agreement With TEVA Pharmaceuticals USA (TEVA) For An Extended Release Oral Drug Product Candidate 2/2/2015 7:54:49 AM
IntelliPharmaCeutics Notes Launch Of 5mg Strength Of Focalin XR(R) Generic By Teva Pharmaceutical Industries Limited (TEVA) 11/20/2014 10:33:07 AM
IntelliPharmaCeutics Reports That The FDA Has Given Its Toronto Manufacturing Facility An "Acceptable" Classification 10/27/2014 7:48:06 AM
IntelliPharmaCeutics Reports Positive Results From A Series Of Phase I Clinical Trials Of Regabatin™ XR (Pregabalin Extended-Release) 10/23/2014 7:17:54 AM
IntelliPharmaCeutics Announces Third Quarter 2014 Results 10/16/2014 7:31:20 AM
IntelliPharmaCeutics Announces Resignation Of Chief Financial Officer 10/1/2014 7:49:18 AM
IntelliPharmaCeutics Augments Its Rexista™ Oxycodone Development Program With Novel Overdose Deterrence Technology 8/29/2014 8:35:04 AM
IntelliPharmaCeutics Announces Second Quarter 2014 Results 7/8/2014 6:17:31 AM
IntelliPharmaCeutics Files Preliminary Base Shelf Prospectus And Shelf Registration Statement 5/21/2014 9:45:01 AM